Insilico Med, 4B Tech partner on neurodegenerative drug discovery

By The Science Advisory Board staff writers

August 27, 2021 -- Insilico Medicine is collaborating with 4B Technologies to develop small-molecule therapies for amyotrophic lateral sclerosis (ALS) and other major neurological diseases.

The companies said the collaboration will leverage Insilico's synthetic biology and synthetic chemistry artificial intelligence platform and 4B Technologies' insights in targeting strategies, biology, translational research, and clinical medicine in the field of neurological diseases.

Insilico uses artificial intelligence to develop kidney fibrosis drug candidate
Insilico Medicine has developed a preclinical candidate for kidney fibrosis that has the desired pharmacological properties and pharmacokinetic profile,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter